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In The Lancet Neurology, Anette Schrag and colleagues1 
provide a valuable contribution to the pursuit of 
prodromal Parkinson’s disease. Why is this important? 
Many clinical trials involving thousands of patients 
and millions of dollars have assessed a range of 
drugs for their putative neuroprotective eﬀ ects 
in Parkinson’s disease.2 These drugs have targeted 
several diﬀ erent pathophysiological processes, 
including oxidative stress, mitochondrial dysfunction, 
apoptosis, excitotoxicity, inﬂ ammation, and failure 
of trophic support. Despite impressive preclinical 
eﬀ ects, none of these agents has modiﬁ ed disease 
progression in patients with Parkinson’s disease. 
The many possible reasons for these failures include 
poor target engagement, inappropriate dose, and 
targeting of the wrong biological pathways, further 
exacerbated by inadequate animal models that might 
not represent the pathogenesis of the human disease. 
However, an important concern that applies to the 
discovery of eﬀ ective neuroprotective therapy in all 
neurodegenerative diseases is the possibility that these 
treatments have been administered too late in the 
degenerative process. Patients participating in such 
trials for Parkinson’s disease have previously been 
viewed as having early disease, since they are generally 
enrolled within months to 2–3 years of the onset of 
their motor symptoms. However, it is now increasingly 
acknowledged that at this so-called early clinical stage 
the disease has become well entrenched and potentially 
advanced beyond a point at which such treatments 
could be expected to have a substantial clinical eﬀ ect, 
especially when given alone and directed towards only 
one pathogenic mechanism or pathway.3 In support 
of this concern, such patients diagnosed as having 
early Parkinson’s disease are known  to have a greater 
than 50–60% deﬁ cit in  the dopaminergic nigrostriatal 
pathway.4 Consequently, interest has grown into the 
possibility of deﬁ ning earlier stages of the disorder 
based on the understanding that the disease might 
actually begin in the peripheral autonomic nervous 
system and the olfactory bulb and spread from there to 
the CNS, typically aﬀ ecting lower brainstem structures 
well before the involvement of the substantia nigra.5 
Substantial evidence supports the occurrence of various 
symptoms many years before the development of 
classical motor parkinsonism. Increased attention to 
the issues of where the disease process begins, how it 
spreads through the nervous system, and how it can be 
diagnosed at earlier prodromal stages has encouraged 
active discussions about the need to redeﬁ ne 
Parkinson’s disease6 and establish new research criteria7 
that can be applied in future clinical trials of disease-
modifying therapies.
Schrag and colleagues now describe the largest and 
most comprehensive assessment of the prediagnostic 
features of Parkinson’s disease reported so far.1 By using 
data recorded in The Health Improvement Network UK 
primary care database, they were able to compare the 
incidence of symptoms in up to 8166 individuals with 
Parkinson’s disease and 46 755 without the disease at 
2, 5, and 10 years before the diagnosis. 2 years before 
clinical diagnosis, many patients may have had overt 
but unappreciated clinical features of Parkinson’s 
disease. However, 5 years before the diagnosis of the 
disease, patients who went on to develop Parkinson’s 
disease had a higher incidence of several symptoms 
than did control participants, including tremor, balance 
problems, depression, anxiety, constipation, postural 
hypotension, dizziness, erectile dysfunction, fatigue, and 
urinary dysfunction. At 10 years before disease onset, 
the incidence of constipation (risk ratio 2·01, 95% CI 
1·62–2·49) and tremor (7·59, 1·11–44·83) were higher 
in those who went on to develop the disease than in 
controls. 
Although this study largely conﬁ rms previous 
ﬁ ndings, such as those from the Honolulu-Asia Aging 
Study8 and from the Mayo Clinic,9 its size is impressive 
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of routine primary care, without recall or selection 
bias towards the diagnosis of Parkinson’s disease. 
The ﬁ ndings further emphasise the frequency and 
complexity of the early premotor or prodromal phase 
of the disorder. Unfortunately, the study design did 
not allow the investigators to calculate relative risks 
for combinations of clinical features. Indeed, without 
a reliable diagnostic biomarker, we will probably need 
such information if patients who are presumed to have 
prodromal Parkinson’s disease are ever to be enrolled 
in neuroprotective trials in the future. An important 
limitation of this type of study is the uncertainty of the 
accuracy of the diagnosis of Parkinson’s disease. In a 
similar population with older disease onset, Adler and 
colleagues10  reported only 26% accuracy for the clinical 
diagnosis of Parkinson’s disease in untreated patients 
or those not clearly responsive to treatment, and only 
53% accuracy in early (<5 years’ duration) Parkinson’s 
disease responsive to medication. Therefore, many 
patients diagnosed with Parkinson’s disease in Schrag 
and colleagues’ study might not have actually had 
the disease of interest. This possibility emphasises the 
crucial need for reliable and widely applicable diagnostic 
biomarkers. When these become available, they will 
probably be applied ﬁ rst to populations enriched for 
the clinical symptoms emphasised in the present study, 
as well as other features known to be associated with 
α-synuclein pathology, such as olfactory dysfunction,11 
rapid eye movement sleep behaviour disorder,12 and 
selected genetic factors,13 in hope of deﬁ ning those 
patients who are most likely to beneﬁ t from the early 
application of eﬀ ective neuroprotective strategies.
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